This conference will gather immunologists, oncologists, technologists, and engineers from academia and industry focused on basic research and clinical translation with the goal of fostering interactions among stakeholders that do not normally interact. To achieves this the conference program will feature new approaches targeting innate cells, application of model systems that replicate aspects of human cancer to inform new therapeutic approaches, the application of protein engineering and materials science to bridge gaps in treatment along with the latest innovations regarding T cell state regulation and application of checkpoint therapy in the clinic.